Biotech Goal Setting: Why It’s a Mistake to Wait for the Board Meeting

We hear it all the time in biotech goal setting: “We can’t set goals until the Board signs off on our corporate strategy.”

The problem? That board meeting often doesn’t happen until February. By then, you’ve lost two of your twelve months and momentum.

At Danforth Health, we’ve worked with more than 1,8000 life science companies. One of the most common missteps we see is delaying biotech goal setting until everything is “finalized”. This hesitation leads to operational drift and signals to your team that alignment and accountability are negotiable. They aren’t.

Start Early. Adjust Later.

Even if your corporate strategy isn’t finalized yet, you can, and should, begin laying the groundwork for effective goal setting in biotech well before the calendar flips to January. 

 “You can always adjust. You can always modify. But if you wait to begin until everything is finalized, you’ve already fallen behind.” Danforth Advisors HR Experts 

A Rolling Approach to Biotech Goal Setting

Begin in December: Host departmental and individual goal-setting sessions using current KPIs, performance metrics, and known priorities. This helps create momentum while keeping teams focused. 

Use a Rolling Framework: When corporate goals are finalized post-board meeting, refine existing goals- don’t restart the process. This prevents duplication of effort and supports better alignment. 

Train Managers to Guide the Process: Not everyone is naturally skilled at facilitating effective goal-setting conversations. And in biotech, where teams are lean and leaders wear many hats, that matters. Invest in manager enablement so that goal conversations are structured, consistent, and clear.  

“A lot of the conversations we see around goal setting are vague. You want clarity on outcomes, not just tasks. Managers need to know how to distinguish between the two.” – Danforth Advisors HR Experts 

Best Practices for Biotech Goal Setting

Use SMART Goals: Make them Specific, Measurable, Achievable, Relevant, and Time-bound. In biotech, metrics matter- especially when tied to funding, product development, and hiring plans. 

Limit Company-Wide Goals to 3–5: Especially at the early stage, less is more. Trying to pursue too many priorities dilutes focus. Danforth Health consistently sees better execution when companies narrow down to a handful of core, high-impact goals. 

Distinguish Goals from Tasks: A goal is a measurable outcome (e.g., “Complete IND submission by Q3”). A task is a step toward that goal (e.g., “Draft protocol outline”). Confusing the two can muddy accountability and derail timelines. 

Cascade and Align: Once corporate goals are in place, ensure every department and employee understands how their work contributes to the larger mission. Alignment isn’t automatic- it’s built through communication and iteration.  

What Happens After You Set Goals?

Effective biotech goal setting doesn’t stop once objectives are written down. Make it a living process:

  • Revisit them monthly or quarterly 
  • Identify gaps, changing priorities, or resource constraints 
  • Adjust without starting from scratch 
  • Review progress transparently with leadership and staff 

Need Help Setting Goals in Biotech?

At Danforth Health, we help biotech companies operationalize clarity-turning strategic priorities into measurable, achievable goals at every level. Don’t let the calendar or boardroom delay your momentum. Reach out today

Mastering CRO Selection in 2026: A Biotech’s Strategy for Lower Risk and Better Outcomes 

Insights by Rene Stephens, Managing Director, Danforth Advisors, a Danforth Health Company 

As we dive into 2026, the stakes for biotech development have never been higher, and a disciplined CRO selection strategy for biotechs has shifted from a competitive advantage to a survival requirement. Capital markets remain unpredictable, the pharma patent cliff continues to reshape partnership dynamics, and regulators are increasing scrutiny around vendor oversight, data integrity, and AI-enabled trial technologies

At the same time, CROs are navigating consolidation, capacity fluctuations, and geopolitical pressures, creating new execution risks even for well-prepared sponsors. In this environment, selecting the wrong CRO can derail entire programs, jeopardize valuation, and undermine investor confidence. That’s why more biotechs are partnering with outsourcing experts who bring data-driven frameworks, real-time market visibility, and negotiation power to one of the most consequential decisions in drug development. 

Why Engage Outsourcing Experts Now 

Navigate the Transformed CRO Landscape 

  • Assess rapidly consolidating global players and their post-M&A service quality 
  • Evaluate emerging regional CROs responding to geopolitical shifts and supply chain diversification 
  • Identify niche providers with specialized therapeutic expertise 
  • Distinguish CROs truly investing in AI/ML capabilities from those simply marketing them 
  • Track financially stable providers amid industry volatility 

Maximize Capital Efficiency (Still Non-Negotiable in 2026) 

  • Extract maximum value from every development dollar with follow-on funding still uncertain 
  • Leverage real-time CRO pricing intelligence as the market recalibrates 
  • Negotiate favorable terms despite limited leverage in a constrained vendor ecosystem 
  • Structure flexible payment terms aligned with funding milestones and runway 
  • Utilize creative deal structures (risk-sharing, milestone-based payments) as CROs compete for quality projects 

De-Risk in a Zero-Margin Environment 

  • Apply rigorous evaluation processes when the timeline slips or trial failures are unaffordable 
  • Identify red flags in operational capacity—resource constraints remain widespread 
  • Assess vendor financial stability as some CROs continue to face economic pressures 
  • Build contractual protections against geopolitical risk and supply chain disruptions 

Secure Strategic Contract Terms 

  • Performance accountability: SLAs with meaningful consequences for delays 
  • Financial protections: Milestone payments, earn-backs, and sponsor-friendly advance structures 
  • Flexibility: Clear change order processes to prevent scope creep 
  • Personnel commitments: Lock in key team members to avoid bait-and-switch scenarios 
  • Termination rights: Sponsor-favorable terms given the asymmetric risk profile 
  • Rate caps: Protection against inflation and arbitrary cost escalations 

Access Real-Time Market Intelligence 

  • Know which CROs are hungry for work vs. operating at capacity 
  • Track regulatory enforcement trends affecting timelines and budgets 
  • Navigate decentralized/hybrid trial models and supporting technologies 
  • Evaluate vendor experience with current FDA/EMA expectations and evolving guidances 

Optimize Internal Resources 

  • Free clinical operations teams to focus on execution rather than vendor management 
  • Avoid learning-curve mistakes that resource-constrained teams cannot afford 
  • Accelerate decision-making when speed-to-clinic determines competitive position 
  • Maintain objectivity and avoid legacy or relationship-based CRO decisions 

Leverage True Negotiating Power 

  • Benefit from outsourcing experts’ market volume and relationships 
  • Access pattern recognition from hundreds of CRO negotiations 
  • Reduce legal spend through streamlined expert-led negotiations 

A Modern CRO Selection Strategy for Biotechs Is No Longer Optional 

In a year defined by operational risk, regulatory pressure, and intense competition for high-quality vendors, having a rigorous CRO selection strategy for biotechs is essential. Small biotechs must execute flawlessly with limited capital and compressed timelines. 

You can’t afford to learn CRO selection through trial and error. 

Danforth Health’s seasoned experts can help you make selection and contracting decisions that protect your program, preserve your capital, and position you for success. Contact our team today.